Latest news with #DeepHealth
Techday NZ
3 days ago
- Health
- Techday NZ
DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies. See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports. The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women. Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant." Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings." See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings. Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound." Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth." According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations. Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers. See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Yahoo
21-05-2025
- Business
- Yahoo
SHINE Announces Two Strategic Appointments to Advance Fusion Technology and Market Expansion
Healthcare technology leader Dr. Gregory Sorensen joins Board of Directors; Defense expert Col. (Ret.) Gregory Van Dyk joins as Strategic Advisor JANESVILLE, Wis., May 21, 2025 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company with commercialized platforms in industrial testing and medical isotopes, today announced the appointments of Dr. Gregory Sorensen, co-founder of DeepHealth and Chief Science Officer of RadNet, and Col. (Ret.) Gregory K. Van Dyk, U.S. Air Force, as strategic advisor to its Board of Directors. These appointments bring deep expertise in healthcare technology and national security to SHINE as the company expands the reach of its fusion applications across commercial and defense markets. "Fusion technology provides real-world solutions to big infrastructure problems in highly specialized markets," said Greg Piefer, founder and CEO of SHINE. "These appointments expand our ability to understand and access these markets quickly. Dr. Sorensen is a strong addition to our already distinguished board, having rare depth in the healthcare space that spans founding, growing, and selling startups through executive operations at multinational conglomerates. Col. Van Dyk brings a career of leadership and widespread connectivity in the radiation effects testing arena, with a specific focus on the effects of DT fusion neutrons." Dr. Sorensen: Guiding Commercial Strategy and Innovation Dr. Sorensen brings decades of experience at the intersection of healthcare, imaging, and technology. As co-founder of DeepHealth (now RadNet's AI division) and former President and CEO of Siemens Healthcare North America, he has led the development and commercialization of transformative medical technologies. He will advise SHINE on strategic growth initiatives, partnerships, and the expansion of its fusion-enabled medical isotope business. "SHINE represents the promise of fusion – not as a science experiment, but as a real-world solution," said Dr. Sorensen. "I'm excited and honored to help guide the company's growth into new healthcare and commercial markets." Col. (Ret.) Van Dyk: Advancing National Security through Fusion Col. (Ret.) Van Dyk, Ph.D. joins SHINE following a distinguished 22-year career in the U.S. Air Force, where he specialized in nuclear engineering, fusion technology, and strategic deterrence. He previously led the Department of Defense's Fusion for National Security initiative and managed a $207 million annual R&D portfolio at the National Nuclear Security Administration along with leading two multi-billion-dollar programs in the Department of Defense. His appointment comes at a critical time as SHINE expands FLARE (Fusion Linear Accelerator for Radiation Effects), a high-energy neutron testing service that enables defense contractors to evaluate the resilience of microelectronics and mission-critical systems in extreme radiation environments. "SHINE's fusion platform is practical, innovative, and timely," said Van Dyk. "FLARE offers a new capability for understanding how our most important defense technologies perform under the toughest conditions." About SHINE Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. View original content to download multimedia: SOURCE SHINE Technologies, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
RadNet, Inc. to Present at the Bank of America Securities 2025 Healthcare Conference on May 13th, 2025
LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2025 Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2025 at 5:00 p.m. Pacific Time. There will be simultaneous and archived webcasts available at Details for RadNet's Presentation: Date: Tuesday, May 13, 2025 Time: 5:00 p.m. Pacific Time Location: Encore Hotel, Las Vegas, NV About RadNet, Inc. RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 398 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit Contact: RadNet, Inc. Mark Stolper, Executive Vice President and Chief Financial Officer 310-445-2800Sign in to access your portfolio
Business Wire
24-04-2025
- Business
- Business Wire
GE HealthCare to feature latest advancements in diagnostic accuracy and patient-centered breast care at SBI 2025 Breast Cancer Imaging Symposium
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a global leader in breast health technology, will feature its latest advancements in diagnostic accuracy and patient-centered breast care during the 2025 Society of Breast Imaging Symposium in Colorado Springs, Co., April 24-27, 2025. This year's showcase will feature new innovations designed to improve breast cancer detection, streamline workflows, and enhance overall patient care. Mammography innovations streamline exam workflows for patient-centered breast care GE HealthCare's latest technologies include the Pristina Via™ mammography system, which provides effortless acquisition, operational excellence, and clinical confidence, which enhances the screening experience for both technologists and patients. This innovation, part of the Senographe Pristina™ platform, provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care. Pristina Via, developed with technologists in mind, takes in-room workflow and patient comfort to the next level through zero-click acquisition functionality when acquiring within protocols, no wait time between exposures 1, and DBT image-to-image cycle times that are up to twice as fast as other mammography systems on the market. 2 Additionally, Pristina Via delivers vendor-neutral prior image comparison, reducing time spent analyzing previous exams and enabling final assessments more efficiently, and Pristina 3D STD mode has the lowest radiation dose for all thickness among the major systems available in the marketplace. 3,4 GE HealthCare to distribute DeepHealth's SmartMammo™ in the U.S. to streamline radiology workflows GE HealthCare continues its strategic collaboration with DeepHealth Inc, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of AI in imaging. The latest milestone includes the commercial availability of SmartMammo™, 510(k) cleared for use with Pristina in U.S. markets. GE HealthCare will distribute SmartMammo to imaging providers in the U.S. alongside the Pristina platform, allowing for integration of advanced AI directly into the company's comprehensive breast imaging portfolio. AI continues to show great promise in breast cancer screening, from early detection and risk prediction to reduced callbacks and more efficient workflows for breast imaging providers. SmartMammo is an AI-powered SaaS solution designed to seamlessly integrate into existing breast cancer diagnostic workflows, enhancing diagnostic accuracy and workflow efficiencies. 5,6. SmartMammo facilitates fast image loading and real-time data rendering of multimodality images, accessible from any workstation and location and integrates directly into the customer's IT stack. DeepHealth's AI-powered breast cancer detection offers automatic lesion localization and degree of suspicion that are effective in diverse populations and dense breast tissue. 5 GE HealthCare's Pristina Via, combined with SmartMammo, provides workflow efficiency for both technologists and radiologists, as well as enhanced image interpretation features with automatic lesion localization. 'We are committed to delivering innovative technologies and end-to-end solutions that address our customer's biggest challenge in breast cancer detection, which is to help clinicians provide efficient, accurate and personalized diagnosis to patients,' says Pooja Pathak, Vice President and General Manager of Mammography at GE HealthCare. 'With Pristina Via and SmartMammo, we have streamlined both exam and radiology workflows in breast cancer screening and diagnostics, enabling clinicians to prioritize patient care.' Latest advancements for breast cancer detection: Invenia™ Automated Breast Ultrasound (ABUS) Premium, the first FDA-approved breast ultrasound indicated as an adjunct to mammography and specifically designed for detecting cancer in dense breasts, will also be showcased at the Symposium. According to studies across the U.S. and Europe, 40% of women and 70% of Asian women have dense breast tissue. 7,8 For patients with dense breasts, the addition of ABUS screening when used with mammography has demonstrated a 35.7% increase in cancer detection compared to mammography alone. 9 The latest Invenia ABUS Premium aims to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology. It features new integrated Verisound™ AI and AI Assistant 10, ensuring faster 11 and reproducible scanning and reading with extraordinary image quality. This increases clinical confidence, addresses workflow productivity, and aids in the detection of breast cancer in women with dense breasts. SenoBright™ HD Contrast Enhanced Mammography (CEM) is a next-level mammogram that helps reduce the masking effect of fibroglandular breast tissue and increases the tumor signal to increase diagnostic confidence. It allows for imaging exams to be conducted in less than seven minutes and enables the detection of lesions that would otherwise go undetected 12, providing patients with answers right away to help them avoid the anxiety of an inconclusive exam. Serena Bright™ is a contrast guided biopsy system that enables providers to see lesions using CEM and sample with certainty. This allows patients to undergo breast biopsy exams using the same mammography equipment, in a familiar setting, with familiar staff, to help relieve some of the stress of a biopsy procedure. To learn more about the personalized breast cancer screening solutions GE HealthCare will be featuring at SBI 2025, please visit booth #407. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. 1 Elapsed time between end of an exposure and system ready in DBT is 2.3s. Measured with ACR Phantom. Pristina Via performance measurement. Data on file GE HealthCare 2024. 2 Image to Image cycle time is the minimum waiting time by the System between two consecutive images. Measured with ACR phantoms for Pristina Via compared to claimed performance of competitor (Dimension 3D_ in Product Data Sheet from Jul-2024) 3 Phantom measurements as of July 2024. Senographe Pristina with default value STD mode. 4 Dose comparison based on NHS Breast Screening Programme equipment reports. 5 U.S. Food and Drug Administration. "Premarket Notification (510k) Summary: K243688." Accessed April 23, 2025. 6 Kim, J., et al. "Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists." Radiology: Artificial Intelligence (2024). 7 Ellison-Loschmann, Lis, et al. 'Interactive and Independent Associations between the Socioeconomic and Objective Built Environment on the Neighbourhood Level and Individual Health: A Systematic Review of Multilevel Studies." PLOS ONE 8, no. 7 (2013): e123456. 8 FDA PMA P110006 summary of safety and effectiveness. 9 AI Assistant available third-party tools include QVCAD™, Koios DS™ Breast, BU-CAD™ and MONCAD ABS. Not available in all regions. 10 Compared to Invenia™ ABUS 2.0. 11 CEM guided biopsy can be performed within 15 minutes from first image to clip placement image. A shorter biopsy lead time and quicker biopsy procedure may speed up a definitive diagnosis and faster path to treatment. Data on file 2020, GE HealthCare. 12 Compared to without contrast J. Sung et al., Radiology 2019; 00:1–8 V. Sorin et al. American Journal of Roentgenology: W267-W274. 10.2214/AJR.17.19355
Yahoo
25-02-2025
- Business
- Yahoo
RadNet's Wholly-Owned Subsidiary, DeepHealth, and ConcertAI's TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization
DeepHealth's cloud-native Diagnostic Suite™ will integrate TeraRecon's SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings. The collaboration will also integrate DeepHealth's clinical AI solutions into TeraRecon's AI ecosystem, augmenting its capabilities and expanding its impact in diagnostic imaging. Both companies will continue to explore new opportunities to leverage each other's AI solutions and distribute AI-driven imaging and workflow automation. LOS ANGELES and SOMERVILLE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT) and ConcertAI's TeraRecon, a leader in medical imaging advanced visualization, clinical AI, and workflow automation, announced today a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow. This collaboration is first designed to create a seamless AI-enabled diagnostic experience for radiologists and imaging specialists through integrating TeraRecon's advanced visualization (AV) technology into DeepHealth OS cloud-native Operating System. Additionally, the collaboration seeks to incorporate DeepHealth's clinical AI solutions into TeraRecon's AI ecosystem, enabling physicians to deliver precise and timely diagnostic interpretations. 'ConcertAI will be aligning its TeraRecon Advanced Visualization and Clinical AI solutions with DeepHealth's AI-enabled operating system to deliver optimized operational and interpretive workflows to radiologists,' said Jeff Elton, PhD, CEO of ConcertAI. 'This two-way collaboration, integrating DeepHealth's clinical AI technology into the TeraRecon AI ecosystem, can provide more radiologists with essential tools to enhance diagnostic efficiency, enabling better patient care.' As imaging volumes continue to rise, radiology departments face increasing pressure to manage workload efficiently while maintaining diagnostic accuracy. AI-powered solutions have demonstrated their potential in streamlining workflows and improving precision, making integrated technologies essential for the future of medical imaging. DeepHealth OS is a secure, scalable, cloud-native platform that personalizes AI-powered workspaces for radiology teams, enabling greater collaboration and efficiency. DeepHealth's Diagnostic Suite™, which harnesses the cloud-native capabilities of DeepHealth OS delivers seamless workflow integration to meet the evolving demands of radiologists through interoperable, reliable, highly scalable unified diagnostic workspace. The integration of TeraRecon's advanced visualization capabilities with DeepHealth's OS and Diagnostic Suite will enhance diagnostic accuracy and efficiency and streamline radiologists' workflows by enabling radiologists to make faster, more informed decisions with greater ease. 'At DeepHealth, we are committed to leveraging advanced AI to enhance radiology workflows, elevate the experience of care teams, and improve patient care,' said Kees Wesdorp, PhD, President and CEO of RadNet's Digital Health division. 'Partnering with TeraRecon allows us to integrate industry-leading visualization and clinical AI technology, equipping radiologists with the tools to improve efficiency and reduce variability. This collaboration strengthens DeepHealth OS, driving innovation in medical imaging.' Additionally, the two companies are exploring the integration of several of DeepHealth's AI-powered cancer screening capabilities into TeraRecon's AI ecosystem, further strengthening TeraRecon's AI-powered imaging solutions and making these essential screening tools more widely available. These enhancements would contribute to TeraRecon's comprehensive cloud-based imaging suite, which spans from diagnosis to research, offering end-to-end advanced imaging solutions for a broader range of healthcare providers. This collaboration marks the beginning of a broader engagement between TeraRecon and DeepHealth, as both companies explore additional areas to integrate AI-driven imaging and workflow automation. By continuing to expand their joint capabilities, they aim to provide radiologists with seamless diagnostic tools that enhance precision, efficiency, and better care delivery. For more information, visit the TeraRecon (#AI-13) and DeepHealth (#507, X5) booths at the European Congress of Radiology 2025, which will be held between 26 February and 2 March in Vienna, Austria. About ConcertAIConcertAI is the leader in predictive and generative AI SaaS and multi-modal data solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at and About DeepHealthDeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. About RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit Forward Looking StatementThis press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, ConcertAI, TeraRecon, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: ConcertAITrebleMcKenzie Covellconcertai@ DeepHealthAndra AxenteCommunications DirectorPhone: +31 614 440971Email:
